Ironwood Pharmaceuticals (IRWD) Cash from Financing Activities (2010 - 2025)

Ironwood Pharmaceuticals (IRWD) has 16 years of Cash from Financing Activities data on file, last reported at $122000.0 in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities rose 100.82% year-over-year to $122000.0; the trailing twelve-month figure through Dec 2025 stood at $216000.0 (up 100.2% YoY), and the FY2025 full-year result was $216000.0, up 100.2% from the prior year.
• Cash from Financing Activities climbed to $122000.0 in Q4 2025, from $88000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $399.1 million in Q2 2023 to a low of -$150.3 million in Q2 2022.
• A 5-year average of -$3.8 million and a median of $6000.0 in 2025 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities jumped 820.0% in 2021 and plunged 9508.78% in 2023, its largest moves.
• Tracing IRWD's Cash from Financing Activities over 5 years: stood at -$18.6 million in 2021, then soared by 115.1% to $2.8 million in 2022, then plunged by 1914.11% to -$50.9 million in 2023, then jumped by 70.75% to -$14.9 million in 2024, then jumped by 100.82% to $122000.0 in 2025.
• Business Quant data shows IRWD's Cash from Financing Activities at $122000.0 in Q4 2025, $88000.0 in Q2 2025, and $6000.0 in Q1 2025.